title: A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix.
abstract: BACKGROUND
  The efficacy and safety of S-1/oxaliplatin (SOX) therapy in patients with recurrent adenocarcinoma of the uterine cervix were examined in a pilot study.
  
  
  METHODS
  S-1 was orally administered for 14 days at a dose of 80-120 mg/body/day to 7 patients with recurrent adenocarcinoma of the uterine cervix, with oxaliplatin being administered intravenously at a dose of 100 mg/m(2) on day 1. Each therapy cycle was 21 days, and the patients received 6 cycles at most. The antitumor effect, adverse events, progression-free survival (PFS), and overall survival (OS) were investigated.
  
  
  RESULTS
  The median age of the patients was 49 years. The antitumor effect was rated as a complete response in 2 patients, partial response in 2, and stable disease in 3. The overall response rate was 57.1 %, and the disease control rate was 100 %. Regarding hematological toxicities of grade 3 or more, leukopenia, neutropenia and thrombocytopenia occurred in 42.9, 28.6 and 14.3 %, respectively; regarding non-hematological toxicities, grade 3 rectovaginal fistula occurred in 14.3 %, as well as grade 2 fatigue in 14.3 % of the patients. The median PFS and OS were 5 months (range 3-9 months) and 7 months (range 4-43 months), respectively.
  
  
  CONCLUSIONS
  These results suggest that SOX therapy is useful for the treatment of recurrent adenocarcinoma of the uterine cervix, having a promising antitumor effect and minimal adverse effects. It was also suggested that SOX therapy may contribute to improving the prognosis for patients with adenocarcinoma of the uterine cervix.
authors.affiliation: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Uchimaru 19-1, Morioka, Iwate, 020-8505, Japan.
authors.forename: Eriko
authors.initials: E
authors.lastname: Takatori
authors.forename: Tadahiro
authors.initials: T
authors.lastname: Shoji
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Suga
authors.forename: Hanae
authors.initials: H
authors.lastname: Niinuma
authors.forename: Yuki
authors.initials: Y
authors.lastname: Miura
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Kaido
authors.forename: Anna
authors.initials: A
authors.lastname: Takada
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kagabu
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takeuchi
authors.forename: Toru
authors.initials: T
authors.lastname: Sugiyama
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology; D000284:Administration, Oral; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D010865:Pilot Projects; D011788:Quality of Life; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology
chemical_list: D004338:Drug Combinations; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid